Business
SCYNEXIS Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement
JERSEY CITY, N.J., Dec. 22, 2025 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that it has received an additional 180-calendar-day extension from the Nasdaq Stock Market (“Nasdaq”) to regain compliance with the minimum bid price requirement, as outlined in Nasdaq Listing Rule 5550(a)(2). The Company now has until June 15, 2026, to meet the require
About this update from Scynexis, Inc.
[{"type":"image","alt":"Scynexis","displaySize":"","headline":null,"caption":"Scynexis","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":68,"url":"https://media.zenfs.com/en/globenewswire.com/6e640369b5a4d26f13c5b336ff4b47c4"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Zxf0PtiEj_fhfiPgUpXZlQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTk1O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/6e640369b5a4d26f13c5b336ff4b47c4","width":300,"height":68}},"lazy":false},{"type":"text","content":"JERSEY CITY, N.J., Dec. 22, 2025 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that it has received an additional 180-calendar-day extension from the Nasdaq Stock Market (“Nasdaq”) to regain compliance with the minimum bid price requirement, as outlined in Nasdaq Listing Rule 5550(a)(2).","length":449,"tagName":"p"},{"type":"text","content":"The Company now has until June 15, 2026, to meet the requirement for its shares of common stock to maintain a closing bid price of at least $1.00 per share for a minimum of ten consecutive business days. Nasdaq granted the extension after determining that SCYNEXIS continues to meet all other continued listing criteria for the Nasdaq Capital Market, including the market value of publicly held shares, and has provided written notice of its intention to cure the deficiency within the extension period, if necessary, through a reverse stock split.","length":553,"tagName":"p"},{"type":"text","content":"“We are grateful for Nasdaq’s decision to grant this 180-day extension, which allows us to continue advancing our strategic objectives,” said David Angulo, M.D., President and Chief Executive Officer. “In the upcoming year we expect to leverage our balance sheet to complete a Phase 1 study of an intravenous (IV) formulation for our next-generation fungerp, SCY-247, as well as generate proof-of-concept Phase 2 data in the oral formulation of SCY-247 for invasive candidiasis infections. SCY-247 is an exciting investigational antifungal with the potential to benefit both hospitalized and community patients with challenging infections and is highly anticipated by the anti-infective scientific community. Lastly, SCYNEXIS remains committed to ful...